Adrenal suppression with chronic dosing of fluticasone propionate compared with budesonide in adult asthmatic patients

D J Clark, B J Lipworth

Abstract

Background – In a previous single dosing comparison between fluticasone propionate and budesonide differences in cortisol levels measured at 08.00 hours were observed at doses in excess of 1000 μg. The aim of this study was to compare the adrenal suppression caused by chronic twice daily dosing with inhaled fluticasone propionate (FP) and budesonide (B) given on a microgram equivalent basis by metered dose inhaler to asthmatic patients.

Methods – Twelve stable asthmatic patients of mean age 29.7 years with forced expiratory volume in one second (FEV₁) 89.0% predicted and mid forced expiratory flow (FEF₂₅₋₇₅) 58.9% predicted, on 400 μg or less of inhaled corticosteroid, were studied in a double blind, placebo controlled, crossover design comparing inhaled budesonide and fluticasone propionate in doses of 250 μg, 500 μg, and 1000 μg twice daily. Each dose was given at 08.00 hours and 22.00 hours for four days by metered dose inhaler with mouth rinsing. Measurements were made of overnight urinary cortisol excretion and plasma cortisol levels at 08.00 hours, 10 hours after the eighth dose.

Results – The plasma cortisol levels (nmol/l) at 08.00 hours showed that fluticasone propionate produced lower cortisol levels than budesonide at all three dose levels: F500 333.8, B500 415.2 (95% CI 2.89 to 134.0); F1000 308.3, B1000 380.3 (95% CI 10.5 to 133.5); F2000 207.3, B2000 318.5 (95% CI 5.8 to 216.7); placebo 399.9. Fluticasone produced greater effects than budesonide on the overnight renal suppression seen with repeated twice daily dosing as this more accurately reflects what may be expected in clinical practice. In theory, with chronic dosing the longer plasma elimination half life of inhaled fluticasone of 14.4 hours compared with 2.3 hours for inhaled budesonide1 and the greater lipophilicity of fluticasone2 will result in greater plasma and tissue retention. This, in conjunction with increased steroid potency and affinity for fluticasone, would be expected to accentuate the differences found between fluticasone and budesonide from the level of suppression already seen with single dosing.

Indeed, in normal subjects a significant increase occurs in adrenal suppression between single and repeated dosing with fluticasone, in keeping with these pharmacological properties.8 The aim of this study was to investigate the suppressive effects of fluticasone propionate and budesonide on adrenal activity across a clinically relevant dose range in asthmatic patients.

Conclusions – With repeated dosing across a dose range of 250–1000 μg twice daily, fluticasone propionate produced significantly greater adrenal suppression than budesonide for both plasma and urinary cortisol. It was therefore possible to demonstrate differences between fluticasone and budesonide at lower doses with chronic dosing from those previously found with single dosing when given on a microgram equivalent basis in asthmatic patients. Factors contributing to the systemic adverse activity profile of fluticasone comprise enhanced receptor potency, prolonged receptor residency time, greater tissue retention, and a longer elimination half life.

Methods

Patients

Twelve asthmatic patients (six women) of mean (SE) age 29.7 (2.4) years completed the study.
The mean forced expiratory volume in one second (FEV₁) was 3.07 (0.07) l (89.0 (3.71)% of predicted) and mid forced expiratory flow (FEF_{25–75}) was 2.49 (0.19) l/s (58.9 (5.1)% of predicted). Haematological and biochemical parameters were normal before entry into the study. All gave written informed consent and approval for the study was given by the Tayside medical ethics committee. All patients had asthma according to the criteria of the American Thoracic Society, and were required to be taking 400 µg/day or less of inhaled corticosteroid. The doses of inhaled corticosteroid taken by the 12 subjects were beclomethasone dipropionate 200 µg/day (two patients), 300 µg/day (one patient), 400 µg/day (six patients), budesonide 400 µg/day (two patients), and one patient took no inhaled steroids. None had received oral corticosteroids within the preceding three months.

PROTOCOL
A double blind, placebo controlled, randomised crossover design was used with twice daily dosing over four days at each dose level. Subjects attended an initial screening visit where FEV₁ and FEF_{25–75} were measured using a Vitalograph Compact spirometer (Vitalograph Ltd, Buckingham, UK), having withheld inhaled bronchodilators for eight hours. FEV₁ was checked on each of the study visits and measurements were only made if it was within 15% of the baseline value. Inhaler technique was assessed using an aerosol inhalation monitor (Vitalograph Ltd) and detailed instructions in correct usage were given at each visit. Subjects were then randomised to receive fluticasone propionate (Flixotide metered dose inhaler (MDI), 250 µg per actuation, Allen and Hanburys, Uxbridge, Middlesex, UK) in doses of 250 µg, 500 µg, and 1000 µg twice daily or budesonide (Pulmicort MDI, 50 µg and 200 µg per actuation, Astra Pharmaceuticals, Kings Langley, Hertfordshire, UK) in doses of 250 µg, 500 µg, and 1000 µg twice daily, each dose being given sequentially for four days. Randomisation was in balanced blocks with six receiving fluticasone first and six budesonide first. Placebo MDI was given for four days at the start of each of the two treatment periods. There was at least a 16 day washout period between the two 12 day drug sequences during which the patients resumed their standard inhaled steroid therapy. The aerosol canisters and plastic actuators were masked and placed in identical boxes in order to blind the treatment with respect to the patient. Each treatment box was dispensed by a different person from the investigator to make the study double blind. Subjects omitted their usual steroid inhaler for the duration of each 12 day sequence and took their bronchodilator inhaler 15 minutes before the study drug at 08.00 hours and 22.00 hours. Mouth rinsing was performed after each of two puffs of their study inhaler. After seven doses at each dose level, immediately before taking the dose at 22.00 hours, subjects emptied their bladder and collected all their overnight urine for 10 hours until the laboratory visit at 08.00 hours the following morning. No further steroid or bronchodilator inhalers were taken until completion of the laboratory visit.

MEASUREMENTS
The subjects attended the laboratory at 07.30 hours, 10 hours after taking the eighth dose of study drug at each dose level. A cannula was inserted into an antecubital fossa vein to allow blood sampling and subjects then rested supine for 30 minutes. After the rest period blood samples were taken for measurement of serum cortisol levels. The total volume of the overnight 10 hour urine specimen was measured and aliquots were kept for assay of cortisol and creatinine levels.

ASSAYS
Serum and urinary cortisol levels were measured using a commercial radioimmunoassay kit (Incastar, Wokingham, Berkshire, UK). The coefficient of variability (CV) for analytical imprecision within the assay was 4.5% and between the assays was 8.1%. Urinary creatinine levels were measured on a Cobas-bio autoanalyser (Roche Products Ltd, Welwyn Garden City, Hertfordshire, UK). The intra-assay CV was 4.55% and interassay was 0.63%.

STATISTICAL ANALYSIS
All data were analysed using a Statgraphics software package (STSC Software Group, Rockville, Maryland, USA). The data were analysed by comparing placebo with both drugs at each dose level using analysis of variance, followed by Duncan’s multiple range testing to observe multiple comparisons. 95% confidence intervals (CI) for differences between treatments were calculated where significant differences were detected. A probability value of p<0.05 (two tailed) was considered significant.

Results
Fluticasone propionate produced greater suppression of both 08.00 hour plasma cortisol and overnight urinary cortisol levels than budesonide (fig 1). This effect was evident even at the lowest dose of 250 µg twice daily. Estimated equivalent potency values by log linear interpolation for percentage suppression of 08.00 hour plasma cortisol levels showed a 3.5:1 ratio from comparison of dose-response curves. In other words, 250 µg fluticasone twice daily was equivalent to 875 µg budesonide twice daily.

Fluticasone produced significantly lower 08.00 hour plasma cortisol levels (nmol/l) than budesonide at all three doses ranging from 250 µg to 1000 µg twice daily. Fluticasone produced significant suppression compared with placebo at all doses, whereas budesonide did not at any dose. Fluticasone also had a greater effect than budesonide on the overnight urinary cortisol/creatinine ratio (nmol/mmol) at all three dose
Adrenal suppression with fluticasone propionate

Figure 1 Mean (SE) plasma cortisol concentrations (A) and overnight urinary cortisol/creatinine ratio (B) with repeated twice daily dosing with budesonide (BUD), fluticasone (FP), and placebo. †Significant difference between budesonide and fluticasone at a given dose level; *significant difference between the steroid dose and placebo (p<0.05).

Discussion

This study shows that fluticasone propionate causes greater adrenal suppression than budesonide when given on a microgram equivalent basis by metered dose inhaler with repeated twice daily dosing to asthmatic patients across a dose range of 250–1000 μg twice daily. A 3.5-fold difference in systemic potency was found between the two drugs which compares with the 5.2-fold difference previously reported by Boorsma et al in normal volunteers for suppression of 08.00 hour cortisol levels. The differential between fluticasone and budesonide is greater with chronic dosing than that seen previously with single dosing. This is in keeping with the pharmacological characteristics of these two drugs, with the longer plasma elimination half life, greater tissue binding, and prolonged receptor binding of fluticasone accentuating its greater gluco-
corticoid potency when given with chronic dosing. In a chronic dosing evaluation of fluticasone 1000 µg twice daily against beclomethasone dipropionate 800 µg twice daily (Diskhaler) significant adrenal suppression of plasma cortisol levels was observed with fluticasone but not beclomethasone, which was maintained throughout the 12 weeks of the evaluation. Furthermore, after a further two weeks washout there was still detectable suppression in the fluticasone group, suggesting prolonged body retention. Another factor, which may partially explain the observed differences between the two drugs is that the fluticasone MDI produces greater lung deposition than the budesonide MDI, although this is based on in vitro data. However, since patients often have difficulty using MDIs, putative differences in deposition may become less important in the real life situation.

Comparison between the results of our previous single dosing study and the present chronic dosing study reveals that this accentuation of the effects of fluticasone results in differences between the two drugs being evident at much lower dose levels with repeated administration. Indeed, with chronic dosing differences in suppression of plasma cortisol levels occurred at a dose of 250 µg twice daily, whereas with single dosing a difference in plasma cortisol levels was only demonstrated above 1000 µg. However, it should be noted that significant differences were observed between single doses of fluticasone 500 µg and budesonide 400 µg using the more sensitive measure of overnight urinary cortisol levels. In our chronic dosing study the urinary cortisol/creatinine ratio, which is as sensitive as 24 hour urinary cortisol measurements, demonstrated significant differences at all doses as would have been predicted from the single dosing results.

The accentuation of the differences between fluticasone and budesonide with chronic compared with single dosing has been demonstrated by Lonnebo et al in healthy volunteers. They compared adrenal suppression (as AUC_{0,20h}) after the first and last doses of fluticasone 1000 µg twice daily via Diskhaler with budesonide 800 µg twice daily via Turbohaler for seven repeated doses and found a much greater increase in suppression between single and repeated dosing for fluticasone (35% versus 25% suppression) than budesonide (34% versus 26%). Boorsma et al also found differences between the two drugs when evaluating much lower doses with a chronic dosing regimen. In healthy volunteers 200 µg fluticasone MDI twice daily produced 18% suppression of the 08.00 hours plasma cortisol level compared with placebo, while the same dose of budesonide, also given via an MDI, produced no significant suppression compared with placebo.

A comparison of our own data from single and chronic dosing studies also highlights the greater degree of suppression at steady state with fluticasone. Compared with placebo, a single 1000 g dose produced 6% suppression of plasma cortisol levels compared with 45% suppression for chronic dosing with 1000 µg twice daily, representing a seven-fold increase. At the 500 µg level a single dose caused no suppression compared with placebo, whereas chronic dosing with 500 µg twice daily produced a 19% fall in 08.00 hour cortisol levels.

Our results agree with those of Grahamen et al who reported suppression of plasma cortisol (as AUC_{0,20h}) of 28% when fluticasone was given as a single dose of 1000 µg via a Diskhaler to healthy volunteers compared with 65% when it was given as 1000 µg twice daily for three and a half days.

In conclusion, our results demonstrate that the greater glucocorticoid potency of fluticasone than budesonide translates directly into increased systemic bioactivity as assessed by adrenal suppression using either plasma or urinary cortisol levels. In fact, the complex interplay between factors including receptor potency, receptor residency time, tissue retention, and plasma elimination half life for fluticasone and budesonide results in significantly greater adrenal suppression for fluticasone with repeated administration at doses as low as 250 µg twice daily. This highlights the necessity for adequate comparative dose ranging studies of inhaled corticosteroids to characterise fully the dose response relationships of this important class of drugs.

The authors wish to thank Mrs L McLearne for performing the biochemical assays.

3. English AF, Neate MS, Quinn DJ, Sareen M. Biological activities of some corticosteroids used in asthma. Am J Respir Crit Care Med 1994;149(Suppl):A212.